Mathematical models of the acute inflammatory response

Current Opinion in Critical Care

Volumn 10, Issue 5, 2004, Pages 383-390

  Vodovotz, Yoram ^a,d   Clermont, Gilles ^a   Chow, Carson ^b   An, Gary ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Jr Hospital of Cook County   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Intensive care; Mathematical model; Methodology; Outcome prediction randomized trials; Sepsis

Indexed keywords

HUMAN; INFECTION; INFLAMMATION; INJURY; MATHEMATICAL MODEL; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; REVIEW; SEPSIS; VALIDATION PROCESS;

ACUTE DISEASE; ANIMALS; HUMANS; INFECTION; INFLAMMATION; MODELS, BIOLOGICAL; PROTEIN C; WOUNDS AND INJURIES;

EID: 4744342992     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ccx.0000139360.30327.69     Document Type: Review

References (40)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al.: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Cri Care Med 2001, 29:1303-1310.
2. Sriskandan S, Cohen J: Gram-positive sepsis: mechanisms and differences from gram-negative sepsis. Infect Dis Clin North Am 1999, 13:397-412.
3. Carballo E, Gilkeson GS, Blackshear PJ: Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice: evidence that monocyte/macrophage progenitors may be responsible for TNFalpha overproduction. J Clin Invest 1997, 100:986-995.
4. Ohshima H, Gilibert I, Bianchini F: Induction of DNA strand breakage and base oxidation by nitroxyl anion through hydroxyl radical production. Free Radic Biol Med 1999, 26:1305-1313.
5. Suzuki S, Takenaka K, Kassell NF, et al.: Hemoglobin augmentation of interleukin-1 β-induced production of nitric oxide in smooth-muscle cells. J Neurosurg 1994, 81:895-901.
6. Rubben A, Eren S, Krein R, Younossi H, et al.: Infrared videoangiofluorography of the skin with indocyanine green-rat random cutaneous flap model and results in man. Microvasc Res 1994, 47:240-251.
7. Mitrovic B, Ignarro LJ, Vinters HV, et al.: Nitric oxide induces necrotic but not apoptotic cell death in oligodendrocytes. Neuroscience 1995, 65:531-539.
8. Freeman BD, Natanson C: Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Invest Drugs 2000, 9:1651-1663.
9. Buchman TG, Cobb JP, Lapedes AS, et al.: Complex systems analysis: a tool for shock research. Shock 2001, 16:248-251.
10. Neugebauer EA, Willy C, Sauerland S: Complexity and non-linearity in shock research: reductionism or synthesis? Shock 2001, 16:252-258.
11. Tjardes T, Neugebauer E: Sepsis research in the next millennium: concentrate on the software rather than the hardware. Shock 2002, 17:1-8.
12. Godin PJ, Buchman TG: Uncoupling of biological oscillators: a complementary hypothesis concerning the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 1996, 24:1107-1116.
13. Seely AJ, Christou NV: Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. Crit Care Med 2000, 28:2193-2200.
14. Kitano H: Systems biology: a brief overview. Science 2002, 295:1662-1664.
15. An G: Agent-based computer simulation and SIRS: building a bridge between basic science and clinical trials. Shock 2001, 16:266-273.
16. Cross AS, Opal SM: A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Ann Intern Med 2003, 138:502-505. This paper highlights the difficulties of designing and carrying out randomized, double-blinded, placebo-controlled clinical trials in sepsis and suggests that successful therapeutic strategies are likely to target more than one pathway or mediator.
17. Bonabeau E: Agent-based modeling: methods and techniques for simulating human systems. Proc Natl Acad Sci USA 2002, 99(Suppl 3):7280-7287.
18. Musante CJ, Lewis AK, Hall K: Small- and large-scale biosimulation applied to drug discovery and development. Drug Discov Today 2002, 7:S192-S196.
19. Clermont G, Chow CC, Constantine GM, et al.: Mathematical and statistical modeling of acute inflammation. Proc Int Fed Classific Soc 2004, in press. This paper describes the design, calibration, and validation of an ODE-based mathematical model of acute inflammation, concentrating on the statistical methods used for the calibration of this model.
20. Vodovotz Y, Chow CC, Bartels J, et al.: In silica models of acute inflammation in animals. Shock 2004, in press. This paper describes the design, calibration, and validation of an DDE-based mathematical model of acute inflammation, concentrating on the application of the model to refinement, reduction, and replacement of animals in pre-clinical studies of sepsis and trauma.
21. Parker SJ, Watkins PE: Experimental models of gram-negative sepsis. Br J Surg 2001, 88:22-30.
22. Bellingan G: Inflammatory cell activation in sepsis. Br Med Bull 1999, 55:12-29.
23. Volk HD, Reinke P, Docke WD: Clinical aspects: from systemic inflammation to "immunoparalysis." Chem Immunol 2000, 74:162-177.
24. Bone RC: Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996, 125:680-687.
25. Pinsky MR: Sepsis: a pro- and anti-inflammatory disequilibrium syndrome. Contrib Nephrol 2001, 354-366.
26. Nathan CF, Hibbs JB Jr: Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 1991, 3:65-70.
27. Johnson ML, Billiar TR: Roles of nitric oxide in surgical infection and sepsis. World J Surg 1998, 22:187-196.
28. Babior BM: Phagocytes and oxidative stress. Am J Med 2000, 109:33-44.
29. Jaeschke H, Smith CW: Mechanisms of neutrophil-induced parenchymal cell injury. J Leukoc Biol 1997, 61:647-653.
30. Harbrecht BG, Billiar TR, Stadler J, et al.: Nitric oxide synthesis serves to reduce hepatic damage during acute murine endotoxemia. Crit Care Med 1992, 20:1568-1574.
31. Florquin S, Amraoui Z, Dubois C, et al.: The protective role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice. J Exp Med 1994, 180:1153-1158.
32. Park J-H, Chang S-H, Lee K-M, et al.: Protective effect of nitric oxide in an endotoxin-induced septic shock. Am J Surg 1996, 171:340-345.
33. An G: In-silico experiments of existing and hypothetical cytokine-directed clinical trials using agent based modeling. Crit Care Med 2004, (In Press) This article demonstrates how the technique of ABM can potentially be used to aid in the search for new anticytokine therapies and the design of subsequent clinical trials.
34. Cleveland J, Shroyer AL, Chen AY, et al.: Off-pump coronary artery bypass grafting decreases risk-adjusted mortality and morbidity. Ann Thorac Surg 2001, 72:1282-1289.
35. Remick DG, Bolgos GR, Siddiqui J, et al.: Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002, 17:463-467.
36. Zenati MS, Billiar TR, Townsend RN, et al.: A brief episode of hypotension increases mortality in critically ill trauma patients. J Trauma 2002, 53:232-236.
37. Clermont G, Bartels J, Kumar R, et al. In silico design of clinical trials: a method coming of age. Crit Care Med 2004, in press. This article demonstrates how an ODE model of acute inflammation can potentially be used to improve the design of anticytokine randomized, placebo-controlled clinical trials.
38. Reinhart K, Menges T, Gardlund B, et al.: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES study. Crit Care Med 2001, 29:765-769.
39. Opal SM, Fisher CJ Jr, Dhainaut JF, et al.: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997, 25:1115-1124.
40. Root RK, Lodato RF, Patrick W, et al.: Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003, 31:367-373. This clinical trial described in this reference was simulated in the ABM and demonstrated a correlation between the negative outcome in the clinical trial and the simulated trial.